Морфометричний аналіз структурних елементів сітчастої оболонки очей щурів лінії Вістар при експериментальному цукровому діабеті

O.E. Dorokhova; L.I. Samoilenko; E.V. Maltsev; O.V. Zborovska

doi:10.31288/oftalmolzh202514146

Authors

O.E. Dorokhova SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
L.I. Samoilenko SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
E.V. Maltsev SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
O.V. Zborovska SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

DOI:

https://doi.org/10.31288/oftalmolzh202514146

Keywords:

diabetic retinopathy, diabetic mellitus, morphometry, retina, experiment, neurodegeneration

Abstract

Purpose: To perform morphometric analysis of retinal structural components in Wistar rats in experimental diabetes mellitus (DM) in an attempt to digitize possible retinal neurodegenerative changes.

Material and Methods: Eight histological globe preparations from Wistar rats were retrospectively reviewed. Of these, five were from Wistar rats with experimental DM, and three, from healthy controls. Total retinal thickness was measured and thicknesses of the following retinal layers were measured: the photoreceptor layer (PRL), outer nuclear layer (ONL), outer retinal layer (ORL), inner nuclear layer (INL), ganglion cell layer (GCL), and nerve fiber layer (NFL). The numbers of neural-cell rows in both nuclear layers were calculated visually. Statistica 5.5 software was used for the analysis of measurement data.

Results: The mean total thickness of the retina was 252.9 ± 8.77 µm for healthy controls and 262.1 ± 8.51 µm for diabetic animals. In controls and diabetic animals, the mean thicknesses for particular retinal layers were as follows: PRL, 75.5 ± 4.14 µm and 74.0 ± 3.85 µm, respectively; ONL, 61.8 ± 3.04 µm and 66.1 ± 4.12 µm, respectively; ORL, 11.6 ± 0.72 µm and 12.4 ± 0.64 µm, respectively; INL, 33.1 ± 1.74 µm and 33.6 ± 1.75 µm, respectively; IRL, 47.2 ± 2.77 µm and 47.9 ± 2.39 µm, respectively; and GCL plus NFL, 23.7 ± 1.44 µm and 28.1 ± 2.57 µm, respectively. In addition, the numbers of neural-cell rows in the ONL were 11.3 ± 0.50, and 11.7 ± 0.59, respectively, and in the INL, 4.6 ± 0.26, µm and 4.7 ± 0.17, respectively. There was no statistically significant difference in thicknesses of retinal layers or numbers of neural-cell rows in the INL and ONL of the retina between normal and diabetic rats.

Conclusion: For Wistar rats with diabetes duration of 3 months, microscopic images of the retina and calculations of thicknesses of individual retinal layers and numbers of neural-cell rows in retinal nuclear layers provided no indication of neurodegenerative changes at this time point.

Author Biographies

O.E. Dorokhova , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Dorokhova O.E., Cand Sc (Med) and Senior Researcher, Department of Ocular Inflammatory Disease

L.I. Samoilenko , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Samoilenko L. I., Junior Researcher and Physician, Consultative Polyclinic

E.V. Maltsev, SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Maltsev E.V., Dr Sc (Med) and Professor and Chief Researcher, Pathomorphology and Electron Microscopy Laboratory

O.V. Zborovska, SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Zborovska O.V. , Dr Sc (Med), Professor and Acting Head, Department of Ocular Inflammatory Disease, and Deputy Research Director

References

Teo ZL, Tham YC, Yu M, Chee, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580-91. https://doi.org/10.1016/j.ophtha.2021.04.027

Hariprasad S, Holecamp N, MacCumber M, et al. Evidence-based management of diabetic eye diseases. Retinal Physician. 2017 April: 4-12.

Xu Y, Jiang Z, Huang J, et al. The association between toll-like receptor 4 polymorphisms and diabetic retinopathy in Chinese patients with type 2 diabetes. Br J Ophthalmol. 2015 Sep;99(9):1301-5. https://doi.org/10.1136/bjophthalmol-2015-306677

Giyasova AO, Yangieva NR. Comparing the effectiveness of brolucizumab therapy alone versus that combined with subthreshold micropulse laser exposure in the treatment of diabetic macular edema. J Ophthalmol (Ukraine). 2023; 2:16-20. https://doi.org/10.31288/oftalmolzh202321620

Malachkova NV, Kyryliuk ML, Komarovska IV. [Blood pressure in patients with diabetic retinopathy, type 2 diabetes mellitus and obesity]. Arkhiv oftalmologii Ukrainy. 2017;5(1):32-37. Russian.

Serdiuk VN, Kyryliuk ML, Ishchenko VA. Mathematical substantiation of the method for assessing the risk of progression of diabetic retinopathy with serum leptin determination in patients with metabolic syndrome and diabetes dellitus. J Ophthalmol (Ukraine). 2018;(2):15-22. https://doi.org/10.31288/oftalmolzh/2018/2/1721

Albini T, Regillo C, Drenser K, et al. Evidence-based management of diabetic eye diseases. Retinal physician. 2016; March: 4-14.

Barth T, Helbig H. [Diabetic retinopathy]. Klin Monatsbl Augenheilkd. 2021 Oct;238(10):1143-1159. https://doi.org/10.1055/a-1545-9927

Alifanov IS, Sakovych V.M. Prognostic risk factors for diabetic retinopathy in patients with type 2 diabetes mellitus. J Ophthalmol (Ukraine). 2022;(6):19-23. https://doi.org/10.31288/oftalmolzh202261923

Cho H, Alwassia AA, Regiatieri CV, et al. Retinal neovascularization secondary to proliferative diabetic retinopathy characterized by spectral domain optical coherence tomography. Retina. 2013;33:542-7. https://doi.org/10.1097/IAE.0b013e3182753b6f

Wykoff CC, YuHJ, Avery RL, et al. Retinal non-perfusion in diabetic retinopathy. Eye (Lond). 2022 Feb;36(2):249-56. https://doi.org/10.1038/s41433-021-01649-0

Walker J, Rykov SA, Suk SA, et al. [Diabetic retinopathy: complexity made simple: a monograph]. Kyiv: Biznes-Logika; 2013. Russian.

Maltsev EV, Zborovska AV, Dorokhova AE. [Fundamental aspects of the development and treatment of diabetic retinopathy]. Odesa: Astroprint; 2018. Russian.

Nevska AO, Pogosian OA, Goncharuk KO, et al. Detecting diabetic retinopathy using an artificial intelligence-based software platform: a pilot study. J Ophthalmol (Ukraine). 2024;1:27-32. https://doi.org/10.31288/oftalmolzh202412731

Rykov SO, Galytska IeP, Zhmuryk DV, Dufynets VA. Association of TLR4 rs1927911 polymorphism with diabetic retinopathy and diabetic macular edema in type 2 diabetic patients. J Ophthalmol (Ukraine). 2024;1(516):20-6. https://doi.org/10.31288/oftalmolzh202412026

Ziablitsev SV, Vodianyk VV. Retinal apoptosis and the effect of tyrosine kinase inhibition in experimental diabetes. J Ophthalmol (Ukraine). 2023;5:34-40. https://doi.org/10.31288/oftalmolzh202353440

Kern TS, Engerman RL. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res. 1994; 13: 863-867. https://doi.org/10.3109/02713689409015087

Alder VA, Su EN, Yu DY, Cringle S, Yu P . Overview of studies on metabolic and vascular regulatory changes in early diabetic retinopathy. Austr NZ J. Ophthalmol. 1998;26(2):141-8. https://doi.org/10.1111/j.1442-9071.1998.tb01530.x

Lieth E, Gardner TV, Barber AJ, et al. Retinal neurodegeneration: early pathology in diabetes. Clin Exp Ophthalmol. 2000 Feb;28(1):3-8. https://doi.org/10.1046/j.1442-9071.2000.00222.x

Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283-90. https://doi.org/10.1016/S0278-5846(03)00023-X